Clinical and Experimental Ophthalmology· 2015Q1· Review
Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review
- 1,074citations
- Q1SCImago
- 2015year
Short summary
Diabetic retinopathy (DR) is a major global cause of vision loss, with rising diabetes incidence posing significant public health and cost challenges for screening programs.
AI-generated from the title and abstract; the full text is not read.
Key points
- Diabetic retinopathy is a primary cause of vision loss in older adults globally.
- Rising diabetes rates increase the burden and cost of DR screening programs.
- Key risk factors include poor glycaemic/blood pressure/lipid control, higher BMI, puberty, pregnancy, and cataract surgery.
- Innovative management and cost-effective screening are needed to mitigate DR's impact.
AI-generated from the title and abstract; the full text is not read.
Abstract
Diabetes retinopathy (DR) is a leading cause of vision loss in middle-aged and elderly people globally. Early detection and prompt treatment allow prevention of diabetes-related visual impairment. Patients with diabetes require regular follow-up with primary care physicians to optimize their glycaemic, blood pressure and lipid control to prevent development and progression of DR and other diabetes-related complications. Other risk factors of DR include higher body mass index, puberty and pregnancy, and cataract surgery. There are weaker associations with some genetic and inflammatory markers. With the rising incidence and prevalence of diabetes and DR, public health systems in both developing and developed countries will be faced with increasing costs of implementation and maintenance of a DR screening program for people with diabetes. To reduce the impact of DR-related visual loss, it is important that all stakeholders continue to look for innovative ways of managing and preventing diabetes, and optimize cost-effective screening programs within the community.
The authors' abstract, as published at the source. Clinical and Experimental Ophthalmology, 2015 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Ophthalmology
OphthalmologyMedicine